All In Biotech

Free tool

FAERS Monitor: Besivance

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022308 or its brand name (Besivance, Besifloxacin Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

969

Serious

423

44% of reports

Hospitalization

157

Death reported

67

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain104
  • vision blurred82
  • eye irritation79
  • off label use78
  • hypersensitivity68
  • ocular hyperaemia60
  • cardiac disorder50
  • chronic kidney disease42
  • drug ineffective36
  • photophobia36
  • impaired healing34
  • foreign body sensation in eyes33
  • corneal oedema30
  • cataract29
  • visual impairment29

Reports by year received

View as table
YearReports
200916
201062
201143
201244
201322
201442
201570
201687
2017106
2018103
201981
202061
202153
202265
202357
202436
202513
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
corneal oedemaSignal30294.5206.68,372
foreign body sensation in eyesSignal33112.980.73,533
photophobiaSignal3641.630.21,385
eye painSignal10440.133.43,928
eye irritationSignal7929.824.12,176
ocular hyperaemiaSignal6027.521.51,506
impaired healingSignal3422.516.2678
vision blurredSignal8213.010.5899
chronic kidney diseaseSignal4212.08.9414
cardiac disorderSignal5011.68.9476
cataractSignal2910.67.4243
hypersensitivitySignal688.06.3410
visual impairmentSignal295.13.592
off label use781.91.636
drug ineffective360.60.410

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.